For additional information please visit wwwbiomarincom102023 805 PM US Food and Drug Administration Approves BioMarins VOXZOGO vosoritide for Children Under 5 Years with Achondroplasia  Oct 20  httpsinvestorsbiomarincom20231020USFoodandDrugAdministrationApprovesBioMarinsVOXZOGORvosoritideforChildrenUnder5Yearswith 911ForwardLooking Statements This press release contains forwardlooking statements about the business prospects of BioMarin Pharmaceutical Inc BioMarin including without limitation statements about the potential impact and role of VOXZOGO in children with achondroplasia including younger children as well as in the treatment of hypochondroplasia and other genetic short stature conditions the development of BioMarins VOXZOGO program including BioMarins expectations regarding timing and the ability to obtain final approval decision from the European Commission for the marketing authorization to expand the indication for VOXZOGO BioMarins plans for the continued clinical development of VOXZOGO including ability to maintain continued approval in the US based on ongoing labelextension studies and confirmatory trials BioMarins plans to initiate a pivotal development program in hypochondroplasia and BioMarins expectations regarding the number of children with achondroplasia that could be prescribed with VOXZOGO and related potential benefits